Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

IPPS rule poses minor changes for ’09

This article was originally published in The Gray Sheet

Executive Summary

Overall, payments for device-dependent hospital procedures will remain relatively stable in fiscal year 2009, according to CMS' final inpatient payment system 1rule released July 31. Only one company, SynCardia Systems, won a new technology add-on payment, a $53,000 bonus per procedure for its CardioWest temporary artificial heart. Overall, CMS says average hospital payments will increase an estimated 4.7% in 2009. To receive full payment in 2009, hospitals must report 13 new quality measures on their claims in addition to the 30 existing measures. Also in the rule, the agency adds to its policy three new preventable hospital-acquired conditions for which Medicare will no longer pay. The conditions include surgical site infections following certain orthopedic procedures and bariatric surgery; disorders brought on by poor glycemic control; and deep vein thrombosis or pulmonary embolism following total knee or hip replacements. The changes take effect Oct. 1 (2"The Gray Sheet" April 21, 2008, p. 3)

You may also be interested in...



CMS Inpatient Payment Proposal Addresses “Charge Compression”

CMS plans to take steps next year to improve the accuracy of its payments to hospitals for high-cost devices, though the agency does not promise as quick of a remedy as sought by manufacturers

US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT026412

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel